# Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

> **NCT05579366** · PHASE1,PHASE2 · RECRUITING · sponsor: **Genmab** · enrollment: 764 (estimated)

## Conditions studied

- High Grade Epithelial Ovarian Cancer
- High Grade Serous Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
- Mesothelioma
- Breast Adenocarcinoma
- Triple Negative Breast Cancer
- Hormone Receptor-positive/Her2 Negative Breast Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Platinum Sensitive Ovarian Cancer (PSOC)
- Primary Refractory Ovarian Cancer
- Uterine Cancer

## Interventions

- **DRUG:** Rina-S
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05579366
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-10
- **Target enrollment:** 764 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579366, "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05579366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*